A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

PHASE3CompletedINTERVENTIONAL
Enrollment

355

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

November 11, 2019

Study Completion Date

February 3, 2020

Conditions
Molluscum Contagiosum
Interventions
DRUG

SB206 12%

Topically once daily

DRUG

Placebo

Topically once daily

Trial Locations (27)

14623

Site #108, Rochester

20774

Site #275, Largo

23294

Site #267, Richmond

29464

Site #255, Mt. Pleasant

32720

Site #292, DeLand

33175

Site #278, Miami

33437

Site #268, Boynton Beach

33613

Site #305, Tampa

37938

Site #271, Knoxville

42301

Site #294, Owensboro

47150

Site #175, New Albany

48346

Site #274, Clarkston

55448

Site #121, Fridley

68144

Site #206, Omaha

70006

Site #289, Metairie

70124

Site #297, New Orleans

71913

Site #101, Hot Springs

75024

Site #293, Plano

77030

Site #167, Houston

80233

Site #257, Thornton

84075

Site #281, Syracuse

85255

Site #266, Scottsdale

90212

Site #282, Beverly Hills

92123

Site #113, San Diego

97223

Site #309, Portland

03801

Site #304, Portsmouth

08009

Site #201, Berlin

All Listed Sponsors
collaborator

Synteract, Inc.

INDUSTRY

lead

Novan, Inc.

INDUSTRY

NCT03927703 - A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC | Biotech Hunter | Biotech Hunter